aTyr Pharma (ATYR) Competitors $5.28 +0.15 (+2.92%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$5.45 +0.17 (+3.22%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR vs. HRMY, IRON, TARS, BEAM, CNTA, ARQT, ADPT, IMCR, SPRY, and EWTXShould you be buying aTyr Pharma stock or one of its competitors? The main competitors of aTyr Pharma include Harmony Biosciences (HRMY), Disc Medicine (IRON), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. aTyr Pharma vs. Its Competitors Harmony Biosciences Disc Medicine Tarsus Pharmaceuticals Beam Therapeutics Centessa Pharmaceuticals Arcutis Biotherapeutics Adaptive Biotechnologies Immunocore ARS Pharmaceuticals Edgewise Therapeutics Harmony Biosciences (NASDAQ:HRMY) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment. Do analysts recommend HRMY or ATYR? Harmony Biosciences currently has a consensus price target of $53.63, suggesting a potential upside of 67.00%. aTyr Pharma has a consensus price target of $20.20, suggesting a potential upside of 282.58%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Harmony Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harmony Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the media prefer HRMY or ATYR? In the previous week, aTyr Pharma had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 3 mentions for aTyr Pharma and 0 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.90 beat aTyr Pharma's score of 0.71 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Overall Sentiment Harmony Biosciences Very Positive aTyr Pharma Positive Which has better earnings & valuation, HRMY or ATYR? Harmony Biosciences has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarmony Biosciences$714.73M2.58$145.49M$2.6212.26aTyr Pharma$230K2,043.13-$64.02M-$0.81-6.52 Which has more risk and volatility, HRMY or ATYR? Harmony Biosciences has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Is HRMY or ATYR more profitable? Harmony Biosciences has a net margin of 20.53% compared to aTyr Pharma's net margin of 0.00%. Harmony Biosciences' return on equity of 24.32% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Harmony Biosciences20.53% 24.32% 15.92% aTyr Pharma N/A -87.09%-64.77% Do insiders and institutionals have more ownership in HRMY or ATYR? 86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 23.6% of Harmony Biosciences shares are held by insiders. Comparatively, 3.7% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryHarmony Biosciences beats aTyr Pharma on 11 of the 16 factors compared between the two stocks. Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATYR vs. The Competition Export to ExcelMetricaTyr PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$456.59M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-6.5221.3126.1919.90Price / Sales2,043.13278.47414.04113.66Price / CashN/A41.4736.1356.90Price / Book6.367.518.025.38Net Income-$64.02M-$55.05M$3.15B$248.50M7 Day Performance-0.56%2.07%1.48%2.06%1 Month Performance-2.04%4.84%3.67%4.86%1 Year PerformanceN/A5.37%34.68%20.24% aTyr Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATYRaTyr Pharma2.7582 of 5 stars$5.28+2.9%$20.20+282.6%N/A$456.59M$230K-6.5253High Trading VolumeHRMYHarmony Biosciences4.8291 of 5 stars$31.93+0.1%$53.63+67.9%+7.0%$1.83B$714.73M12.19200Positive NewsIRONDisc Medicine2.0118 of 5 stars$51.68+0.1%$96.70+87.1%+27.8%$1.79BN/A-13.1830Positive NewsTARSTarsus Pharmaceuticals2.2687 of 5 stars$40.60-0.1%$66.67+64.2%+46.8%$1.71B$182.95M-14.8750BEAMBeam Therapeutics1.9127 of 5 stars$16.71-0.3%$48.75+191.7%-11.9%$1.69B$63.52M-3.62510CNTACentessa Pharmaceuticals2.9685 of 5 stars$13.00+4.6%$27.89+114.5%+56.7%$1.66B$6.85M-7.18200ARQTArcutis Biotherapeutics2.0541 of 5 stars$14.40+4.2%$18.80+30.6%+48.0%$1.65B$196.54M-13.85150Positive NewsADPTAdaptive Biotechnologies3.4624 of 5 stars$10.56+1.7%$10.57+0.1%+240.7%$1.58B$178.96M-11.00790News CoverageIMCRImmunocore2.5011 of 5 stars$31.12-0.7%$58.89+89.2%-5.9%$1.57B$310.20M-72.37320SPRYARS Pharmaceuticals2.9444 of 5 stars$16.57+4.9%$31.00+87.1%+93.4%$1.55B$89.15M-103.5690Insider TradeEWTXEdgewise Therapeutics2.6574 of 5 stars$14.18-0.8%$39.78+180.5%-29.2%$1.50BN/A-9.1560News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Harmony Biosciences Alternatives Disc Medicine Alternatives Tarsus Pharmaceuticals Alternatives Beam Therapeutics Alternatives Centessa Pharmaceuticals Alternatives Arcutis Biotherapeutics Alternatives Adaptive Biotechnologies Alternatives Immunocore Alternatives ARS Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATYR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
